Large majorities of Republicans (73%) and MAGA supporters (83%) say it is likely that the Trump administration will lower drug prices for people like them, while far fewer independents (33%) and just one in 10 Democrats (9%) say that it is likely
In January, New York Magazine reported that 30 percent of the peptides one company tested were either mislabeled, under- or overdosed, or contaminated with toxins or foreign bacteria. Thats part of why we have a regulator like FDA, Zettler points out
Compounded GLP-1 programs operating in 2026 must navigate the post-shortage legal framework, which includes restrictions on compounding drugs that are commercially available drugs under sections 503A and 503B of the FD&C Act
The mechanism remains unclear
Tier 3: Trading companies and intermediaries (purity unknown) This is where most quality problems originate
Ask your doctor specifically why Toujeo was chosen over a GLP-1 agonist